Skip to content

The Effect of a Mindfulness-Based Stress Reduction Program on Depression and Quality of Life in Cancer Patients: A Meta-Analysis Study.

Esma Özmaya, Sevda Uzun, Tufan Aytaç

Holistic Nursing Practice October 10, 2024 DOI: 10.1097/HNP.0000000000000705 (opens in new tab)

Study at a glance

AI-extracted from the abstract
Characteristics Meta-analysis Peer reviewed
Population Cancer patients
Intervention Mindfulness-based stress reduction program
Topics Depression Meditation
Key findings Mindfulness-based stress reduction programs significantly reduce depression and improve quality of life in cancer patients, with several moderators influencing the effect on quality of life.

Abstract

Mindfulness-based interventions have been receiving growing attention in cancer care. This study was performed to determine the effect of a mindfulness-based stress reduction program on depression and quality of life in cancer patients. The screenings in the study were performed in January to May 2023 through the Cochrane Central Register of Controlled Trials (CENTRAL), PubMed, Web of Science, Science Direct, and YÖK Thesis Center databases. After the reviews, 14 studies were included in the study. This meta-analysis showed that mindfulness-based stress reduction programs were effective on depression (SMD: -0.363; 95% CI: -0.711 to 0.015; Z = -2.042; P = .041; I2 = 85.229%) and quality of life (SMD: 0.363; 95 CI%: 0.111-0.615; Z = 2.822; P = .005; I2 = 75.222%). The type of cancer (SMD: 0.385; CI: between 0.005 and 0.528; P = .000); duration of therapy (SMD: 0.243; CI: between 0.093 and 0.393; P = .002); the person providing therapy (SMD: 0.335; CI: between 0.133 and 0.507; P = .001); scale used (SMD: 0.290; CI: between 0.148 and 0.432; P = .000); and the origin of the study (SMD: 0.298; CI: between 0.158 and 0.438; P = .000) moderators were found to play a role in the effectiveness of a mindfulness-based stress reduction program on the quality of life of cancer patients. The mindfulness-based stress reduction program yields positive outcomes by reducing depression, enhancing the quality of life in cancer patients, and promoting overall mental well-being in individuals.

Comparable studies

Other systematic reviews and meta-analyses on depression, most cited first.

Study Year Design Participants
Ketamine and Other NMDA Antagonists: Early Clinical Trials and Possible Mechanisms in Depression Participants with major depression in placebo-controlled, double-blind, randomized... 2015 Systematic review and meta-analysis
Side-effects associated with ketamine use in depression: a systematic review. Patients with depression 2018 Systematic review
Comparative efficacy of racemic ketamine and esketamine for depression: a systematic review and meta-analysis Adults with unipolar or bipolar major depression 2020 Systematic review and meta-analysis n = 1,877
Single-dose infusion ketamine and non-ketamine N-methyl-D-aspartate receptor antagonists for unipolar and bipolar depression: a meta-analysis of efficacy, safety and time trajectories Patients with major depressive disorder or bipolar depression 2016 Systematic review and meta-analysis n = 588
Therapeutic effects of classic serotonergic psychedelics: A systematic review of modern‐era clinical studies Patients with cancer- or illness-related anxiety and depression, major depressive... 2020 Systematic review n = 188

Citations in the library

Explore topics